Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.33 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310762 | 0.85 | MAP4K1 (0.36) | MAP4K1MAP4K3KITFLT3DYRK1A | |
| SCHEMBL24310733 | 0.83 | IGF1R (0.34) | MAP4K1MAP4K3KITFLT3 | |
| SCHEMBL24309929 | 0.83 | MAP4K1 (0.33) | MAP4K1MAP4K3KITFLT3GSK3B | |
| SCHEMBL29566770 | 0.83 | BRD4 (0.36) | MAP4K1MAP4K3GSK3BDYRK1ABRD4 | |
| SCHEMBL24309993 | 0.83 | BRD4 (0.36) | MAP4K1MAP4K3GSK3BDYRK1ABRD4 | |
| SCHEMBL24310172 | 0.82 | MAP4K1 (0.36) | MAP4K1MAP4K3KITFLT3GSK3B | |
| SCHEMBL24309769 | 0.82 | MAP4K1 (0.32) | MAP4K1MAP4K3 | |
| SCHEMBL24309869 | 0.81 | CHEK1 (0.33) | MAP4K1MAP4K3 | |
| SCHEMBL24309840 | 0.81 | MAP4K1 (0.32) | MAP4K1MAP4K3 | |
| SCHEMBL24310201 | 0.81 | MAP4K1 (0.32) | MAP4K1MAP4K3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |